|
Hemato-oncology / Review
Germline DDX41 mutations in myeloid neoplasms: a comprehensive review
Je-Hwan Lee, Eun-Hye Hur, Young-Uk Cho
Korean J Intern Med. 2026;41(3):396-410. Published online May 1, 2026
DEAD-box helicase 41 (DDX41)-associated myeloid neoplasms represent a distinct hereditary cancer syndrome and have emerged as the most common form of genetic predisposition to adult-onset hematologic malignancies, accounting for 3–5% of adults with myelodysplastic syndrome and acute myeloid..
|
|
|
Hemato-oncology / Original Article
The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
Mihee Kim, TaeHyung Kim, Seo-Yeon Ahn, Jun Hyung Lee, Ju Heon Park, Myung-Geun Shin, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi, Mi Yeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
Korean J Intern Med. 2023;38(4):534-545. Published online June 9, 2023
Background/Aims: We evaluated the role of next-generation sequencing (NGS)-based disease monitoring for elderly patients diagnosed with acute myeloid leukemia (AML) who received decitabine therapy.
Methods: A total of 123 patients aged > 65 years with AML who received decitabine were eligible. We an..
|
|
|
Hemato-oncology / Original Article
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
Yoo Jin Na, Eun Sang Yu, Dae Sik Kim, Dae-Hee Lee, Sang Cheul Oh, Chul Won Choi
Korean J Intern Med. 2021;36(Suppl 1):S196-S206. Published online April 3, 2020
Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a ..
|
|
|
Hemato-oncology / Original Article
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong
Korean J Intern Med. 2021;36(6):1450-1458. Published online November 1, 2021
Background/Aims: Adherence to tyrosine kinase inhibitors (TKIs) has become a critical aspect of care in chronic myeloid leukemia (CML). We aimed to examine the association of TKI adherence with overall survival (OS) outcomes in Korean patients diagnosed with CML and treated with TKIs using data from..
|
|
|
Hemato-oncology / Original Article
Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia
Heejoo Han, Ja Min Byun, Dong-Yeop Shin, Sung-Soo Yoon, Youngil Koh, Junshik Hong, Inho Kim, Chansup Lee, Hyeonjoo Yoo, Hongseok Yun, Man Jin Kim, Sung Im Cho, Moon-Woo Seong, Sung Sup Park
Korean J Intern Med. 2021;36(2):401-412. Published online August 20, 2020
Background/Aims: Understanding leukemic stem cell (LSC) is important for acute myeloid leukemia (AML) treatment. However, association of LSC with patient prognosis and genetic information in AML patients is unclear.
Methods: Here we investigated the associations between genetic information and the ..
|
|
|
Hemato-oncology / Original Article
Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia
Yun-Gyoo Lee, Inho Kim, Somi Oh, Dong-Yeop Shin, Youngil Koh, Keun-Wook Lee
Korean J Intern Med. 2019;34(1):178-183. Published online November 27, 2017
Background/Aims: To evaluate and select microRNAs relevant to acute myeloid leukemia (AML) pathogenesis, we analyzed differential microRNA expression by quantitative small RNA next-generation sequencing using duplicate marrow samples from individual AML patients.
Methods: For this study, we obtaine..
|
|
|
Hemato-oncology / Original Article
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
Dae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choi
Korean J Intern Med. 2016;31(2):357-366. Published online February 15, 2016
Background/Aims: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment ..
|
|
|
Case Report
Neutrophilic Myositis without Cutaneous Involvement as the First Manifestation of Acute Myeloid Leukemia
Mi-Kyeong Kim, Jeong Woo Park, Se Hoon Park, Soo Mee Bang, Jae Gul Chung, Jeong Yeal Ahn, Han Joo Baek
Korean J Intern Med. 2005;20(4):346-348. Published online December 31, 2005
Muscle involvement in acute febrile neutrophilic dermatosis is uncommon. Herein, we report a case of acute febrile neutrophilic myositis, without cutaneous involvement, as the first manifestation of acute myeloid leukemia. The patient was a 35-year-old male, referred due to painful swelling of th..
|
|
|
